Close Menu

NEW YORK (GenomeWeb) – Agendia said today that Institut Curie has joined up as a co-validation partner for an in vitro diagnostic kit version of the company's MammaPrint and BluePrint breast cancer assays.

Agendia said this June that it was extending its relationship with Agilent Technologies to develop an RNA sequencing-based version of its existing MammaPrint and BluePrint tests that could be used by labs in a more decentralized testing setting.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Mar
26
Sponsored by
PerkinElmer

This webinar will address the current status and future directions for massively high-throughput genomics for plant and animal breeding and research.

Mar
27
Sponsored by
Swift Biosciences

Sequencing workflows require library quantification and normalization to ensure data quality and reduce cost. 

Mar
28
Sponsored by
Qiagen

The Human Gene Mutation Database (HGMD) is a manually curated, comprehensive collection of disease-causing, germline mutations. Since 1996, a team of experts has manually catalogued over a quarter of a million mutations for the database.  

Apr
11
Sponsored by
Bionano Genomics

This webinar will review a recent study that applied whole-genome sequencing and optical genome mapping to identify a large number of previously undetected somatic structural variants in leukemia samples.